New combo therapy aims to stop liver cancer recurrence in High-Risk patients
NCT ID NCT06644937
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether combining a liver-directed procedure (TACE) with the drug icaritin can help prevent liver cancer from coming back after surgery in patients at high risk of recurrence. Thirty adults who had their liver cancer completely removed will receive up to 4 TACE treatments plus 6 months of icaritin pills. The main goal is to see how many patients remain cancer-free after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Icaritin (Acoradine) combined with transcatheter arterial chemoembolization (TACE)
What this could lead to
If it works, this could offer a new way to delay or prevent liver cancer from coming back after surgery in patients at high risk.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The combination treatment also carries risks from both TACE and icaritin, and may not improve recurrence rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhujiang Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••